Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib and Radiotherapy in First-line EGFR+ NSCLC With Brain Metastases
NCT04905550Phase 2Unknown
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Intracranial Progress Free Survival up to 4 years. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04905550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905550.